Disclosed are thyroid receptor ligand compounds of formula (I), wherein the substituents are as described within the specification. Examples of compounds of formula (I) include: 2-(((3,5-dichloro-4-(4-hydroxy-3-isopropyl phenoxy)benzylidene)amino)oxy) acetic acid and 2-(((3,5-dibromo-4-((6-hydroxy-[1,1-biphenyl]-3-yl)oxy)benzylidene)amino)oxy)butanoic acid. Further disclosed is a pharmaceutical composition comprising a compound of formula (I), and the use of a compound of formula (I) in the manufacture of a medicament for preventing or treating diseases caused by dyslipidemia obesity. Also disclosed are compounds as intermediates for the preparation of a compound of formula (I).
